From the publishers of JADPRO

HR+ HER2- Breast Cancer Resource Center

Advertisement

Low skeletal muscle radiodensity predicts response to CDK4/6 inhibitors plus aromatase inhibitors in advanced breast cancer

Last Updated: Tuesday, March 11, 2025

In a retrospective study, researchers investigated the association between skeletal muscle radiodensity (SMD) and therapeutic responses in patients with advanced HR+ HER2- breast cancer. Data from 247 patients showed that low SMD predicted poor treatment outcomes among patients undergoing first-line treatment with aromatase inhibitors and CDK4/6 inhibitors.  

Journal of Cachexia, Sarcopenia, and Muscle
Advertisement
News & Literature Highlights
Advertisement
Advertisement